Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Ze LiKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University Shenyang 110016 Liaoning P. R. China mscheng@syphu.edu.cn.
Dongfeng ZhangBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences 1 Xian Nong Tan Street Beijing 100050 P. R. China joyce@imm.ac.cn zhaohongyicool@imm.ac.cn.ORCID https://orcid.org/0000-0003-0870-3782
Hanxun WangKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University Shenyang 110016 Liaoning P. R. China mscheng@syphu.edu.cn.ORCID https://orcid.org/0000-0002-1139-6384
Haihong HuangBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences 1 Xian Nong Tan Street Beijing 100050 P. R. China joyce@imm.ac.cn zhaohongyicool@imm.ac.cn.
Maosheng ChengKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University Shenyang 110016 Liaoning P. R. China mscheng@syphu.edu.cn.ORCID https://orcid.org/0000-0001-9073-4806
Hongyi ZhaoBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences 1 Xian Nong Tan Street Beijing 100050 P. R. China joyce@imm.ac.cn zhaohongyicool@imm.ac.cn.ORCID https://orcid.org/0000-0003-1622-5768
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
A mild and straightforward synthetic route to tri-, tetra-, and pentacyclic 1,6-naphthyridin-4-amines is presented. The protocol involves CF
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mild synthesis of fused polycyclic 1,6-naphthyridin-4-amines and their optical properties. · full record | OpenQuestion